Cyramza® Approved for Stomach Cancer


The drug Cyramza (ramucirumab) has been approved by the United States Food and Drug Administration (FDA) for the treatment of gastric (stomach) cancer, as well as gastroesophgeal junction adenocarcinoma (cancer that forms at the junction of the esophagus and stomach).

Cyramza is referred to as an angiogenesis inhibitor, which works by blocking the formation of blood vessels to the cancer cells.

The indication for Cyramza includes patients with advanced cancer that is not able to be surgically removed after treatment with standard chemothearpyl.

The clinical trial that prompted approval included 355 patients with advanced gastric or gastroesophageal junction cancer. Of these patients, two-thirds were treated with cyramza, while the other third received placebo.

Median survival was 5.2 months for patients treated with cyramza, compared with 3.8 months for those who received placebo.
Growth of cancer was delayed among patients treated with cyramza.
A second clinical trial that compared cyramza plus paclitaxel (chemotherapy agent) to paclitaxel along also demonstrated an improvement in survival with the addition of cyramza.
Reference: United States Food and Drug Administration (FDA): press release. FDA approves cyramza for stomach cancer. Available at: